Hospital Bed. Source: Adobe Stock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Ramsay Health Care (ASX: RHC) has delivered a sharp improvement in FY26 earnings, with stronger hospital activity, improved operating performance and tighter cost management helping the healthcare group lift both underlying and statutory profit.

Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.

The hospital operator reported net profit after tax of $329.2 million for the year ended June 30, compared with $24 million a year earlier. The result was ahead of the $311.4 million Visible Alpha consensus.

Revenue increased to $18.7 billion, from $17.84 billion in FY25, while underlying NPAT rose 22.9% to $364.1 million. Underlying EBIT also increased 11.8% to $1.162 billion, with underlying earnings per share rising 27% to 151.0 cents.

Ramsay said its Australian hospital operations continued to build momentum, with higher patient activity, an increase in more complex cases, better utilisation of operating theatres and improved cost control supporting the result.

The group also recorded positive net cash flow across its Australian and UK businesses. Group EBIT margin improved by 30 basis points to 6.2%, while returns on invested capital also strengthened.

The improved earnings performance has flowed through to shareholders, with Ramsay declaring a fully franked final dividend of 48.5 cents per share, taking the full year payout to 91 cents per share.

Chief executive Natalie Davis pointed to stronger transformation across the Australian business, alongside continued clinical performance and improvements in capital returns.

Looking ahead, Ramsay expects further EBIT growth and margin improvement in FY27 as it continues to focus on hospital activity, cost management and capital discipline.

Join the discussion: See what’s trending right now on HotCopper, Australia’s largest stock forum, and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.

rhc by the numbers
More From The Market Online
Ai gen brain scan

FDA approval not enough to revive local Telix Pharma bulls as stock pulls back again

While it’s generally a true maxim that for ASX-listed healthcare companies US FDA approvals tend to be a major upside catalyst, this week

Argenica Therapeutics’ concussion data selected for international neurotrauma congress

Argenica Therapeutics' recent preclinical concussion study has been selected for oral presentation at an international meeting…
Cancer concept

Prescient Therapeutics nears a pivotal moment as PTX-100 Phase 2a trial hits key milestone

As cancer rates around the world climb for a range of reasons, one of the most active frontiers in the oncology space remains
Medical project manager using a laptop

PYC Therapeutics doses first patient in OLE study supporting kidney disease candidate

PYC Therapeutics has dosed the first patient in a Part D open-label extension (OLE) of an…